CVS Health stock prepares for 2028 split after Q3 beat

CVS Health announced on Wednesday, November 4, that it intends to separate its operations into two independent, publicly traded companies by the first half of 2028. The company said the plan followed a strategic review and would give each business a more focused agenda, capital structure and management team. The announcement was made alongside third-quarter results and higher full-year guidance in a CVS Health release.

CVS Health stock traded at 79.76 euros on Lang & Schwarz at 13:30 CET on Wednesday, November 11, 2026.

Two businesses with different profiles

The healthcare solutions company will retain Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The retail pharmacy company, which will be called CVS Pharmacy, will include approximately 9,000 pharmacies, mail pharmacy operations, MinuteClinic and Health100 technology services.

David Joyner, currently CVS Health's chairman and chief executive, is expected to lead the healthcare solutions company. Prem Shah, the current group president, is slated to become chief executive of CVS Pharmacy. Existing CVS Health shareholders are expected to own shares in both companies after the separation.

CVS said the transaction is intended to be tax-free for the company and its shareholders under U.S. federal tax rules. Completion remains subject to customary conditions, including final board approval, the effectiveness of a Form 10 registration statement and confirmation of the intended tax treatment. Until completion, CVS Health will continue to operate as one company.

Stronger quarter supports guidance

For the quarter ended September 30, CVS Health reported revenue of 108.4 billion U.S. dollars, up 5.4 percent from the prior-year period. Adjusted earnings per share rose to 2.09 U.S. dollars from 1.60 U.S. dollars, while adjusted operating income increased 21.2 percent to 4.194 billion U.S. dollars, according to the company's third-quarter release.

The Health Care Benefits segment benefited from a lower medical benefit ratio of 91.3 percent, compared with 92.8 percent a year earlier. Adjusted operating income in the segment reached 912 million U.S. dollars, compared with 314 million U.S. dollars in the prior-year quarter. Pharmacy and Consumer Wellness adjusted operating income increased 10.6 percent to 1.635 billion U.S. dollars, despite lower segment revenue amid pricing and reimbursement pressure.

CVS raised its 2026 adjusted EPS outlook to at least 8.20 U.S. dollars from a previous range of 7.90 to 8.10 U.S. dollars. Cash flow from operations is now expected to reach at least 15.5 billion U.S. dollars, compared with a previous floor of 11.5 billion U.S. dollars. The company also expects full-year revenue of at least 420 billion U.S. dollars.

Execution will shape the investment case

The planned separation gives investors a future choice between a healthcare solutions company centered on insurance, pharmacy benefits and care delivery and a retail pharmacy company focused on stores and community care. The allocation of debt, dividends, stranded costs and standalone expenses will be important as CVS provides more transaction details.

Management said both companies are expected to have investment-grade ratings and strong free cash flow. Elevated healthcare costs, pharmacy reimbursement pressure and the complexity of separating shared operations remain key issues for the stock while the plan moves through its approval process.

Broader risk appetite remains relevant for investors following the S&P 500, although the planned separation is company-specific.

Further transaction updates, regulatory filings and subsequent quarterly results will determine whether CVS can convert the stronger operating trend into a credible standalone structure. More news and analyses on CVS Health stock.